Sandoz Group AG (XSWX:SDZ) Non Operating Income: CHF0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:SDZ Sandoz Group AG XSWX:SDZ
11 GF Score
Price CHF64.00
! 3 Warning Signs
View Full Analysis

What is Sandoz Group AG Non Operating Income?

Sandoz Group AG XSWX:SDZ -2.68% 11 Non Operating Income is CHF0 Mil as of Dec. 2025. GuruFocus rates XSWX:SDZ with a GF Score™ of 11/100. The stock has 3 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Sandoz Group AG's Non Operating Income for the six months ended in Dec. 2025 was CHF0 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was CHF0 Mil.

Sandoz Group AG Non Operating Income Related Terms

Sandoz Group AG Non Operating Income Historical Data

* Premium members only.

The historical data trend for Sandoz Group AG's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sandoz Group AG Non Operating Income Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Non Operating Income
0.00 0.00 0.00 0.00

Sandoz Group AG Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Non Operating Income Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
XSWX:SDZ
11GF Score
Sandoz Group AG XSWX:SDZ
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sandoz Group AG Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of CHF0 Mil mean?
Sandoz Group AG (XSWX:SDZ) has a Non Operating Income of CHF0 Mil as of Dec. 2025. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Sandoz Group AG and its competitors.
Is Sandoz Group AG's Non Operating Income too high?
Sandoz Group AG's current Non Operating Income is CHF0 Mil. Overall, Sandoz Group AG has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Non Operating Income compare to ZTS and UTHR?
Sandoz Group AG's Non Operating Income of CHF0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Drug Manufacturers company?
A good Non Operating Income depends on the Drug Manufacturers industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Sandoz Group AG and its competitors. Sandoz Group AG's current Non Operating Income is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (XSWX:SDZ) has a current Non Operating Income of CHF0 Mil. The current Non Operating Income is CHF0 Mil. Sandoz Group AG's overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Sandoz Group AG (XSWX:SDZ), the current Non Operating Income is CHF0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sandoz Group AG Business Description

Address Centralbahnstrasse 4, Basel, CHE, 4051
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
11GF Score

Get the complete analysis for XSWX:SDZ

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF64.00
Price